Vivos Therapeutics (VVOS) Current Deferred Revenue (2019 - 2026)

Vivos Therapeutics (VVOS) has 8 years of Current Deferred Revenue data on file, last reported at $495000.0 in Q1 2026.

• Current Deferred Revenue for Q1 2026 came in at $495000.0, down 16.67% year-over-year; the trailing twelve-month figure through Mar 2026 was $495000.0 (down 16.67% YoY), and the FY2025 annual result was $479000.0, down 51.76% from the prior year.
• Current Deferred Revenue improved to $495000.0 in Q1 2026 per VVOS's latest filing, from $479000.0 in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $3.0 million in Q4 2022 and troughed at $479000.0 in Q4 2025.
• A 5-year average of $1.8 million and a median of $2.2 million in 2022 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2023 and 2025: Current Deferred Revenue soared 34.06% in 2023, then tumbled 79.73% in 2025.
• A 5-year view of Current Deferred Revenue shows it stood at $3.0 million in 2022, then slipped by 20.11% to $2.4 million in 2023, then slumped by 59.09% to $993000.0 in 2024, then plunged by 51.76% to $479000.0 in 2025, then advanced by 3.34% to $495000.0 in 2026.
• Business Quant data shows VVOS's Current Deferred Revenue at $495000.0 in Q1 2026, $479000.0 in Q4 2025, and $538000.0 in Q3 2025.